Webinar: Why Patient-Specific Insulin Dosing Matters. Watch for free today!
Blog
Inpatient Glucose Management: Part 2
ADA and Joint Commission Guidelines for Best Practices
In part 1 of this series, we explained the risks and complications associated with inpatient glucose control. We learned that occurrences include hyperglycemia, hypoglycemia, poor treatment and/or lack of control, and hospital-acquired conditions.
The American Diabetes Association (ADA) and The Joint Commission have created recommendations for diabetes care in the hospital. Some of the best practices include:
- Insulin – The preferred method of glycemic control in the hospital setting.
- Sliding scale – This retrospective method of insulin dosing is strongly discouraged in the hospital setting as the sole method of treatment.
- Glucose range – Once insulin therapy begins, a target glucose range of 140-180 mg/dL (7.8-10.0 mmol/L) is recommended for most critically ill and non-critically ill patients.
- Stringent targets – The target range of 110-140 mg/dL is appropriate for select critically ill patients without increasing the risk of hypoglycemia.
In part 3 of this series, we will uncover the facts behind the positive outcomes of inpatient glucose control.
Related posts

Blog
Celebrating Nurses Who Lead: Why Nurse-Led Training Sets the Standard
Celebrating Nurses Who Lead: Why Nurse-Led Training Sets the Standard
Honoring Nurse Educators for National Nurses Week As we celebrate National Nurses Week, we're shining a light on the incredible work nurses do every day—not just at the bedside, but also as educators, leaders, and change agents. At Monarch Medical ...

Blog
Every 30 Seconds: The Decision Pressure Nurses Face
Every 30 Seconds: The Decision Pressure Nurses Face
Honoring Nurses Week 2025 Every May, we take a moment to celebrate the nurses who are the backbone of our healthcare system. But their impact isn't just something to recognize once a year - it's felt every second of every ...

News
Monarch Medical Technologies Announces FDA Clearance of EndoTool IV 3.1 with Dosing Mode For Hyperglycemic Crisis Management
Monarch Medical Technologies Announces FDA Clearance of EndoTool IV 3.1 with Dosing Mode For Hyperglycemic Crisis Management
Strengthening Hospital Response to Hyperglycemic Crisis: EndoTool may be used in the treatment of hyperglycemic crises, including conditions such as Euglycemic DKA (EuDKA), DKA, and HHNK. Monarch Medical Technologies, the only patient-specific insulin dosing solution for hospitals, today announced FDA ...
Get in Touch
Ready to get started?
Fill in your details and one of our friendly team members will be in touch to show you how easily EndoTool can support your hospital.
"*" indicates required fields